About the Company
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida. The company is developing medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CPRX News
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company
Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great ...
Catalyst Pharmaceuticals, Inc. (CPRX)
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or ...
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton ...
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
Source: Catalyst Pharmaceuticals, Inc. Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.
First Week of May 17th Options Trading For Catalyst Pharmaceuticals (CPRX)
Investors in Catalyst Pharmaceuticals Inc (Symbol: CPRX) saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.
Discover the impact of the Inflation Reduction Act on generic drugs, benefiting certain stocks in the pharmaceutical sector.
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and ...
Catalyst Pharmaceuticals Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Catalyst Pharmaceuticals Inc CPRX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...